Articles

Results 1 to 5 of 24


Federal Circuit Axes Amgen Antibody Patents, Finding Lack of Enablement

USA - February 18 2021 The Federal Circuit considered its 35 U.S.C. § 112 enablement case law and found that “the enablement inquiry for claims that include functional…

Matthew Weiss

Rehearing Denied in Federal Circuit Hatch-Waxman Venue Case

USA - January 28 2021 The Federal Circuit has spoken. In a per curiam opinion, it denied Valeant’s petition for rehearing by the panel and rehearing en banc. A case…

Jordan Engelhardt, Matthew Weiss

Opposition to Rehearing Filed in Major Federal Circuit Case Narrowing Hatch-Waxman Venue

USA - January 11 2021 Last week, Mylan filed a brief in opposition to Valeant’s petition for rehearing en banc in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc., No…

Jordan Engelhardt, Matthew Weiss

Rehearing Requested in Major Federal Circuit Case Narrowing Venue in Hatch-Waxman Cases

USA - December 14 2020 Earlier this month, Valeant Pharmaceuticals North America LLC (“Valeant”) filed a petition for rehearing en banc in Valeant Pharms. N. Am. LLC v…

Jordan Engelhardt, Matthew Weiss

For the First Time Since TC Heartland, the Federal Circuit Addresses Venue in an ANDA Case the Holding May Also Impact BPCIA Litigation

USA - November 19 2020 On November 5, 2020, in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc., No. 2019-2402, the Federal Circuit held that venue in Hatch-Waxman cases…

Jordan Engelhardt, Aron Fischer, William F. Cavanaugh, Jr., Barbara L. Mullin, Matthew Weiss